A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, phase I study designed to determine the MTD or oral
topotecan as a radiosensitizing agent in the treatment of rectal cancer patients. Sequential
cohorts of three patients will be given increasing doses of oral topotecan and fixed doses of
concurrent radiation (45GY) over five weeks.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute